Tag: weight loss drugs
New weight loss drug reduces AHI in certain patients
April 17, 2024HME News Staff
INDIANAPOLIS – Eli Lilly and Company’s tirzepatide injection diabetes and weight loss drug may help reduce AHI in patients with sleep apnea, according to the results of the company’s phase 3 clinical trials. The Surmount-OSA Study 1 evaluated tirzepatide in adults with moderate-to-severe OSA and obesity who were not on PAP therapy for 52 weeks. Tirzepatide led to a mean AHI reduction from baseline of 27.4 events per hour compared to a mean AHI reduction from baseline of 4.8 events...
Indie pharmacies report shortages
February 15, 2024HME News Staff
ALEXANDRIA, Va. – Nearly 96% of independent pharmacy owners and managers report experiencing shortages or backorders of GLP-1 drugs, according to the results of a new survey from the National Community Pharmacists Association. Most report ordering the drugs upon paid claims (63%) rather than keeping a stock on hand (37%) due to high prices and low reimbursement from pharmacy benefit managers, the survey found. “GLP-1s have been tremendously popular over the last couple of years...
ResMed starts tracking patients on both weight loss drugs, CPAP therapy
January 5, 2024Liz Beaulieu, Editor
YARMOUTH, Maine – ResMed CEO Mick Farrell believes that, based on the company’s early research, weight loss drugs will be a “net positive” for patient flow for sleep apnea.
“I mean, I think there's $1 trillion worth of market cap now from these (pharmaceutical) companies and they will turn that into marketing to bring people in for the miracle drug,” he said during a recent conference call to discuss ResMed’s latest financial results. “And...
Industry weighs potential impact of weight loss drugs
November 17, 2023Theresa Flaherty, Managing Editor
YARMOUTH, Maine – Respondents to a recent HME Newspoll aren’t quite sure what to make of the weight loss drug craze and whether or not it will impact demand for certain HME.
Nearly 40% of respondents say the drugs, which are known as GLP-1s and which include brand names like Ozempic and Wegovy, could reduce demand for CPAP devices, as obesity is among the most important risk factors for sleep apnea.
“Over time, I think this will have a huge impact on PAP devices...